Clopidogrel Desensitization After Drug-Eluting Stent Placement

Journal of the American College of Cardiology

Volumn 50, Issue 21, 2007, Pages 2039-2043

  von Tiehl, Karl F ^a   Price, Matthew J ^a   Valencia, Rafael ^a   Ludington, Katherine J ^a   Teirstein, Paul S ^a   Simon, Ronald A ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ANAPHYLAXIS; ANGINA PECTORIS; ARTICLE; BRONCHUS HYPERREACTIVITY; DESENSITIZATION; DOSE CALCULATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG SUBSTITUTION; FOLLOW UP; HUMAN; ISCHEMIA; OUTPATIENT; PRIORITY JOURNAL; PRURITUS; REMISSION; RISK BENEFIT ANALYSIS; SKIN ALLERGY; STANDARDIZATION; STENOSIS;

CORONARY ARTERY DISEASE; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 36049023495     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.08.016     Document Type: Article

References (18)

1. Moses J.W., Leon M.B., Pompa J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
3. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
4. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
5. Plavix (clopidogrel bisulfate) package insert (2006), Bristol-Myers Squibb Company & Sanofi-Synthelabo, New York, NY revised May
6. Steinhubl S.R., Tan W.A., Topol E.J., and EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 281 (1999) 806-810
7. Patterson R., DeSwarte R.D., Greenberger P.A., and Grammer L.C. Drug allergy and protocols for management of drug allergies. N Engl Reg Allergy Proc 7 (1986) 325-342
8. Stevenson D.D. Desensitization of aspirin-sensitive asthmatics: a therapeutic alternative?. J Asthma 201 (1983) 31-38
9. Gollapudi R.R., Teirstein P.S., Stevenson D.D., and Simon R.A. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 292 (2004) 3017-3023
10. Camara M.G., and Almeda F.Q. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Intervent 65 (2005) 525-527
11. Walker N.E., Fasano M.B., and Horwitz P.A. Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience. J Invasive Cardiol 18 (2006) 341-344
12. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
13. Cutlip D.E., Baim D.S., Ho K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
14. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
15. Nebeker J.R., Virmani R., Bennett C.L., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
16. Doogue M.P., Begg E.J., and Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever and neutropenia. Mayo Clin Proc 80 (2005) 1368-1370
17. Lee-Wong M., Gadhvi D., and Resnick D. Clopidogrel desensitization. Ann Allergy Asthma Immunol 96 (2006) 756-757
18. Naclerio R., Mizrahi E., and Adkinson Jr. N.F. Immunologic observations during desensitization and maintenance of clinical tolerance to penicillin. J Allergy Clin Immunol 71 (1983) 294-301